Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | MAP2 | P11137 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399225 | 0.84 | MAPT (0.42) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL13872830 | 0.84 | ALDH1A1 (0.56) | ALDH1A1CYP1A2HPGDXBP1CYP2C19 | |
| Hydrochloric Acid SCHEMBL4138993 | 0.83 | ALDH1A1 (0.55) | ALDH1A1CYP1A2HPGDXBP1CYP2C19 | |
| SCHEMBL4893031 | 0.82 | MAPT (0.71) | ALDH1A1CYP1A2HPGDXBP1CYP2C19 | |
| SCHEMBL14594304 | 0.77 | MEN1 (0.51) | ALDH1A1CYP1A2HPGDXBP1CYP2C19 | |
| SCHEMBL3961023 | 0.77 | MAPT (0.52) | ALDH1A1CYP1A2HPGDXBP1CYP2C19 | |
| SCHEMBL3888738 | 0.75 | AR (0.59) | ALDH1A1CYP1A2HPGDXBP1CYP2C19 | |
| SCHEMBL20568724 | 0.74 | ALDH1A1 (0.51) | ALDH1A1CYP1A2HPGDXBP1CYP2C19 | |
| SCHEMBL3957157 | 0.74 | HIF1A (0.52) | ALDH1A1CYP1A2HPGDXBP1CYP2C19 | |
| SCHEMBL7377399 | 0.73 | GABRA1 (0.52) | ALDH1A1CYP1A2HPGDXBP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-2036906-A1 | Azaindoles as inhibitors of soluble adenylate cyclase | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009030725-A2 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009030725-A2 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098189-A1 | AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | ADCY1, ADCY5, ADCY2 | ALDH1A1 327/4885CYP1A2 355/4885HPGD 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.